Henry Schein, Inc. reported second quarter 2026 financial results on August 4, 2026, posting GAAP diluted EPS of $0.82 compared to $0.70 in the prior year period. Total net sales reached $3.5 billion, a 6.7% increase from Q2 2025, driven by 4.6% internal growth and favorable foreign currency impacts. The company raised its full-year 2026 guidance, projecting non-GAAP diluted EPS between $5.29 and $5.39, sales growth of 4.5% to 5.5%, and Adjusted EBITDA growth in the mid-to-high-single digits. During the quarter, Henry Schein repurchased approximately 2.6 million shares for $200 million, leaving $455 million authorized for future buybacks. The company operates as a global provider of healthcare solutions, products, and technology platforms to office-based dental and medical practitioners.
